HIV-1 reverse transcriptase and protease mutations for drug-resistance detection among treatment-experienced and naïve HIV-infected individuals

Farah Bokharaei-Salim, Maryam Esghaei, Khadijeh Khanaliha, Saeed Kalantari, Arezoo Marjani, Atousa Fakhim, Hossein Keyvani, Farah Bokharaei-Salim, Maryam Esghaei, Khadijeh Khanaliha, Saeed Kalantari, Arezoo Marjani, Atousa Fakhim, Hossein Keyvani

Abstract

Background: The presence of drug resistance mutations (DRMs) against antiretroviral agents is one of the main concerns in the clinical management of individuals with human immunodeficiency virus-1 (HIV-1) infection, especially in regions of the world where treatment options are limited. The current study aimed at assessing the prevalence of HIV-1 DRMs among naïve and treatment-experienced HIV-1-infected patients in Iran.

Methods: From April 2013 to September 2018, the HIV-1 protease and reverse transcriptase genes were amplified and sequenced in plasma specimens of 60 newly diagnosed antiretroviral-naive individuals and 46 participants receiving antiretroviral therapies (ARTs) for at least six months with an HIV viral load of more than 1000 IU/mL to determine the HIV-1 DRMs and subtypes.

Results: Among the 60 treatment-naïve HIV-1-infected participants, 8.3% were infected with HIV-1 variants with surveillance DRMs (SDRMs). The SDRMs, D67N and D67E, belonged to the NRTIs class in two patients and K103N and V106A belonged to the NNRTIs class in three patients. The phylogenetic analysis showed that 91.7% of the subjects were infected with subtype CRF35_AD, followed by subtype B (5.0%) and CRF01_AE (3.3%). Among the 46 ART-experienced participants, 33 (71.7%) carried HIV-1 variants with SDRMs (9.1% against PIs, 78.8% against NRTIs, and 100% against NNRTIs). M46I and I47V were the most common mutations for PIs, M184V was the most common mutation for the NRTIs, and K103N/S was the most common mutation for NNRTIs. Phylogenetic analysis of the polymerase region showed that all of the 46 HIV-1-infected patients who failed on ART carried CRF35_AD.

Conclusions: The moderate prevalence of SDRMs (8.3%) in treatment-naïve and ART-failed (77.1%) Iranian patients with HIV-1-infection emphasizes the need for systematic viral load monitoring, expanding drug resistance testing, carefully surveilling individuals on ART regimens, and facilitating access to new antiretrovirals by health authorities.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Phylogenetic tree was dawned using…
Fig 1. Phylogenetic tree was dawned using MEGA7 software based on HIV-1 protease and reverse transcriptase nucleotide sequences (1015 bp) obtained from plasma samples of 60 treatment-naïve Iranian patients with HIV-1 infection and those corresponding to various HIV subtypes/CRFs obtained from the GenBank HIV database.
The Phylogenetic tree was constructed using the neighbor-joining method; the bootstrap values over 70% obtained after 1000 replicates are also shown.
Fig 2. Phylogenetic tree was dawned using…
Fig 2. Phylogenetic tree was dawned using MEGA7 software based on HIV-1 protease and reverse transcriptase nucleotide sequences (1015 bp) obtained from plasma samples of 46 treatment-experienced Iranian patients with HIV infection and those corresponding to various HIV subtypes/CRFs obtained from the GenBank HIV database.
The phylogenetic tree was constructed using the neighbor-joining method; the bootstrap values over 70% obtained after 1000 replicates are also shown.

References

    1. sheet GHAsf. Global HIV & AIDS statistics 2018 fact sheet[online] . 2018.
    1. National AIDS Committee Secretariat M, Education oHaM. Islamic Republic of Iran AIDS Progress Report. March 2015.
    1. Sinha S, Gupta K, Khan NH, Mandal D, Kohli M, Das BK, et al. Higher Frequency of HIV-1 Drug Resistance and Increased Nucleoside Reverse Transcriptase Inhibitor Mutations among the HIV-1 Positive Antiretroviral Therapy-Naive patients Coinfected With Mycobacterium tuberculosis Compared With Only HIV Infection in India. Infectious diseases. 2018;11:1178633718788870 10.1177/1178633718788870
    1. Paydary K, Khaghani P, Emamzadeh-Fard S, Alinaghi SA, Baesi K. The emergence of drug resistant HIV variants and novel anti-retroviral therapy. Asian Pacific journal of tropical biomedicine. 2013;3(7):515–22. 10.1016/S2221-1691(13)60106-9
    1. Naziri H, Baesi K, Moradi A, Aghasadeghi MR, Tabarraei A, McFarland W, et al. Antiretroviral drug resistance mutations in naive and experienced patients in Shiraz, Iran, 2014. Arch Virol. 2016;161(9):2503–9. 10.1007/s00705-016-2955-z
    1. Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. Aids. 2007;21(2):215–23. 10.1097/QAD.0b013e328011e691
    1. Pillay D. Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther. 2004;9(5):695–702.
    1. Weinstein MC, Goldie SJ, Losina E, Cohen CJ, Baxter JD, Zhang H, et al. Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness. Annals of internal medicine. 2001;134(6):440–50. 10.7326/0003-4819-134-6-200103200-00008
    1. Farrokhi M, Moallemi S, Shirkoohi R, Golmohammadi R, Ahsani-Nasab S, Sardashti S, et al. Antiretroviral Drug Resistance Mutations among HIV Treatment Failure Patients in Tehran, Iran. Iranian journal of public health. 2017;46(9):1256–64.
    1. Manosuthi W, Ongwandee S, Bhakeecheep S, Leechawengwongs M, Ruxrungtham K, Phanuphak P, et al. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand. AIDS research and therapy. 2015;12:12 10.1186/s12981-015-0053-z
    1. Vahabpour R, Bokharaei-Salim F, Kalantari S, Garshasbi S, Monavari SH, Esghaei M, et al. HIV-1 genetic diversity and transmitted drug resistance frequency among Iranian treatment-naive, sexually infected individuals. Arch Virol. 2017;162(6):1477–85. 10.1007/s00705-017-3228-1
    1. Ibe S, Shibata N, Utsumi M, Kaneda T. Selection of human immunodeficiency virus type 1 variants with an insertion mutation in the p6(gag) and p6(pol) genes under highly active antiretroviral therapy. Microbiol Immunol. 2003;47(1):71–9. 10.1111/j.1348-0421.2003.tb02788.x
    1. Chiba-Mizutani T, Miura H, Matsuda M, Matsuda Z, Yokomaku Y, Miyauchi K, et al. Use of new T-cell-based cell lines expressing two luciferase reporters for accurately evaluating susceptibility to anti-human immunodeficiency virus type 1 drugs. Journal of clinical microbiology. 2007;45(2):477–87. 10.1128/JCM.01708-06
    1. Nii-Trebi NI, Ibe S, Barnor JS, Ishikawa K, Brandful JA, Ofori SB, et al. HIV-1 drug-resistance surveillance among treatment-experienced and -naive patients after the implementation of antiretroviral therapy in Ghana. PLoS One. 2013;8(8):e71972 10.1371/journal.pone.0071972
    1. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009;4(3):e4724 10.1371/journal.pone.0004724
    1. Coovadia A, Hunt G, Abrams EJ, Sherman G, Meyers T, Barry G, et al. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2009;48(4):462–72.
    1. Mohamad S, Deris ZZ, Yusoff NK, Ariffin TAATM, Shueb RH. Assessing subtypes and drug resistance mutations among HIV-1 infected children who failed antiretroviral therapy in Kelantan, Malaysia. The Brazilian Journal of Infectious Diseases. 2012;16(3):284–8.
    1. Los Alamos, HIV database.[online] . January 2019.
    1. Memarnejadian A, Menbari S, Mansouri SA, Sadeghi L, Vahabpour R, Aghasadeghi MR, et al. Transmitted Drug Resistance Mutations in Antiretroviral-Naive Injection Drug Users with Chronic HIV-1 Infection in Iran. PLoS One. 2015;10(5):e0126955 10.1371/journal.pone.0126955
    1. Baesi K, Ravanshad M, Ghanbarisafari M, Saberfar E, Seyedalinaghi S, Volk JE. Antiretroviral drug resistance among antiretroviral-naive and treatment experienced patients infected with HIV in Iran. J Med Virol. 2014;86(7):1093–8. 10.1002/jmv.23898
    1. Jahanbakhsh F, Hattori J, Matsuda M, Ibe S, Monavari SH, Memarnejadian A, et al. Prevalence of transmitted HIV drug resistance in Iran between 2010 and 2011. PLoS One. 2013;8(4):e61864 10.1371/journal.pone.0061864
    1. Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. The Lancet Infectious diseases. 2018;18(3):346–55. 10.1016/S1473-3099(17)30702-8
    1. Stecher M, Chaillon A, Eis-Hubinger AM, Lehmann C, Fatkenheuer G, Wasmuth JC, et al. Pretreatment human immunodeficiency virus type 1 (HIV-1) drug resistance in transmission clusters of the Cologne-Bonn region, Germany. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2019;25(2):253 e1–e4.
    1. Paraskevis D, Kostaki E, Gargalianos P, Xylomenos G, Lazanas M, Chini M, et al. Transmission Dynamics of HIV-1 Drug Resistance among Treatment-Naive Individuals in Greece: The Added Value of Molecular Epidemiology to Public Health. Genes. 2017;8(11).
    1. Bahls LD, Canezin PH, Reiche EMV, Fernandez JCC, Dias JRC, Meneguetti VAF, et al. Moderate prevalence of HIV-1 transmitted drug resistance mutations in southern Brazil. AIDS research and therapy. 2019;16(1):4 10.1186/s12981-019-0219-1
    1. Assoumou L, Bocket L, Pallier C, Grude M, Ait-Namane R, Izopet J, et al. Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France. J Antimicrob Chemother. 2019.
    1. Bokharaei-Salim F, Keyvani H, Esghaei M, Zare-Karizi S, Dermenaki-Farahani SS, Hesami-Zadeh K, et al. Prevalence of occult hepatitis C virus infection in the Iranian patients with human immunodeficiency virus infection. J Med Virol. 2016;88(11):1960–6. 10.1002/jmv.24474
    1. Shah S, Xing H, Altaf A, Chen B, Liao L, Jia Y, et al. Antiretroviral drug resistance mutations among treated and treatment-naive patients in Pakistan: diversity of the HIV type 1 pol gene in Pakistan. AIDS Res Hum Retroviruses. 2011;27(12):1277–82. 10.1089/aid.2010.0324
    1. von Wyl V, Yerly S, Burgisser P, Klimkait T, Battegay M, Bernasconi E, et al. Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2009;48(7):979–87.
    1. Assoumou L, Charpentier C, Recordon-Pinson P, Grude M, Pallier C, Morand-Joubert L, et al. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study. J Antimicrob Chemother. 2017;72(6):1769–73. 10.1093/jac/dkx042
    1. Lu X, Zhao H, Zhang Y, Wang W, Zhao C, Li Y, et al. HIV-1 drug-resistant mutations and related risk factors among HIV-1-positive individuals experiencing treatment failure in Hebei Province, China. AIDS research and therapy. 2017;14(1):4 10.1186/s12981-017-0133-3
    1. Li J, Xu Y, Liu J, Yang B, Yang C, Zhang M, et al. Drug resistance evolution in patients with human immunodeficiency virus-1 under long-term antiretroviral treatment-failure in Yunnan Province, China. Virology journal. 2019;16(1):5 10.1186/s12985-018-1112-6
    1. Tsai HC, Chen IT, Wu KS, Tseng YT, Sy CL, Chen JK, et al. High rate of HIV-1 drug resistance in treatment failure patients in Taiwan, 2009–2014. Infection and drug resistance. 2017;10:343–52. 10.2147/IDR.S146584
    1. Kityo C, Thompson J, Nankya I, Hoppe A, Ndashimye E, Warambwa C, et al. HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa. J Acquir Immune Defic Syndr. 2017;75(2):e45–e54. 10.1097/QAI.0000000000001285
    1. Dong K, Ye L, Leng Y, Liang S, Feng L, Yang H, et al. Prevalence of HIV-1 Drug Resistance among Patients with Antiretroviral Therapy Failure in Sichuan, China, 2010–2016. The Tohoku journal of experimental medicine. 2019;247(1):1–12. 10.1620/tjem.247.1
    1. O'Donnell MR, Wolf A, Werner L, Horsburgh CR, Padayatchi N. Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: a prospective cohort study. J Acquir Immune Defic Syndr. 2014;67(1):22–9. 10.1097/QAI.0000000000000221
    1. Bokharaei-Salim F, Kalantari S, Gholamypour Z, Najafi A, Keyvani H, Esghaei M, et al. Investigation of the effects of a prevention of mother-to-child HIV transmission program among Iranian neonates. Arch Virol. 2018;163(5):1179–85. 10.1007/s00705-017-3661-1
    1. Mohraz M, Tayeri K, Namdari Tabar H, Bayat Jozani Z, Sadeghi L, SeyedAlinaghi S, et al. Evaluation of Acquired HIV Drug Resistance among People Living with HIV Who Have Taken Antiretroviral Therapy for 9–15 Months in 14 Triangular Clinics in Iran, 2015–2016. Intervirology. 2018;61(6):292–300. 10.1159/000497036
    1. Geretti AM. HIV-1 subtypes: epidemiology and significance for HIV management. Current opinion in infectious diseases. 2006;19(1):1–7. 10.1097/01.qco.0000200293.45532.68
    1. Lal RB, Chakrabarti S, Yang C. Impact of genetic diversity of HIV-1 on diagnosis, antiretroviral therapy & vaccine development. The Indian journal of medical research. 2005;121(4):287–314.
    1. Frater AJ, Dunn DT, Beardall AJ, Ariyoshi K, Clarke JR, McClure MO, et al. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS. 2002;16(8):1139–46. 10.1097/00002030-200205240-00007
    1. Bocket L, Cheret A, Deuffic-Burban S, Choisy P, Gerard Y, de la Tribonniere X, et al. Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness. Antivir Ther. 2005;10(2):247–54.
    1. Vasan A, Renjifo B, Hertzmark E, Chaplin B, Msamanga G, Essex M, et al. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2006;42(6):843–52.
    1. Kiwanuka N, Laeyendecker O, Robb M, Kigozi G, Arroyo M, McCutchan F, et al. Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. The Journal of infectious diseases. 2008;197(5):707–13. 10.1086/527416
    1. Baeten JM, Chohan B, Lavreys L, Chohan V, McClelland RS, Certain L, et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. The Journal of infectious diseases. 2007;195(8):1177–80. 10.1086/512682

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren